scholarly journals Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2

Esophagus ◽  
2018 ◽  
Vol 16 (1) ◽  
pp. 25-43 ◽  
Author(s):  
Yuko Kitagawa ◽  
Takashi Uno ◽  
Tsuneo Oyama ◽  
Ken Kato ◽  
Hiroyuki Kato ◽  
...  
Esophagus ◽  
2018 ◽  
Vol 16 (1) ◽  
pp. 1-24 ◽  
Author(s):  
Yuko Kitagawa ◽  
Takashi Uno ◽  
Tsuneo Oyama ◽  
Ken Kato ◽  
Hiroyuki Kato ◽  
...  

Esophagus ◽  
2020 ◽  
Author(s):  
Masayuki Watanabe ◽  
◽  
Yuji Tachimori ◽  
Tsuneo Oyama ◽  
Yasushi Toh ◽  
...  

Abstract Background Esophageal cancer is the eighth most common cause of cancer mortality in Japan. More than 11,000 people had died from esophageal cancer in 2018. The Japan Esophageal Society has collected the data on patients' characteristics, performed treatment, and outcomes annually. Methods We analyzed the data of patients who had first visited the participating hospitals in 2013. In 2019, the data collection method was changed from an electronic submission to a web-based data collection using the National Clinical Database (NCD). Japanese Classification of Esophageal Cancer 10th by the Japan Esophageal Society (JES) and UICC TNM Classification 7th were used for cancer staging Results A total of 8019 cases were registered from 334 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.8% and 6.3%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 88.3%, 32.4%, 24.4%, and 59.3%, respectively. Esophagectomy was performed in 4910 cases. The operative and the hospital mortality rates were 0.77% and 1.98%, respectively. The survival curves showed a good discriminatory ability both in the clinical and pathologic stages by the JES system. The 5-year survival rate of patients with pStage IV in the UICC classification that included patients with supraclavicular node metastasis was better than that of patients with pStage IVb in JES classification. Conclusion We hope this report contributes to improving all aspects of the diagnosis and treatment of esophageal cancer in Japan.


Esophagus ◽  
2020 ◽  
Vol 17 (2) ◽  
pp. 122-126 ◽  
Author(s):  
Kenji Nemoto ◽  
Shohei Kawashiro ◽  
Yasushi Toh ◽  
Hodaka Numasaki ◽  
Yuji Tachimori ◽  
...  

Abstract Background In definitive chemoradiotherapy (CRTx) for esophageal cancer, a radiotherapy (RT) dose of 50.4 Gy in 28 fractions has been the standard in many countries, while 60 Gy in 30 fractions has been frequently used in Japan. To clarify the optimal RT dose in CRTx for esophageal cancer, we compared clinical outcomes with the two doses using data from the Comprehensive Registry of Esophageal Cancer in Japan by the Japan Esophageal Society (JES). Methods Of the patients enrolled in the registry for 2015–2017 surveys (patients treated between 2009 and 2011), 996 patients who received definitive CRTx with 50.4 Gy or 60 Gy for thoracic esophageal cancer were eligible for analysis. Results The complete response (CR) rates in the 50.4 Gy and 60 Gy groups were 49.1% and 46.4%, respectively (p = 0.5851). The 5-year overall survival (OS) rates in the 50.4 Gy group and 60 Gy group for stages I, II/III and IV were 64.2% and 57.2%, 35.0% and 27.0%, and 18.0% and 15.3%, respectively. Since no significant difference was found between the two groups, the 50.4 Gy group was not inferior to the 60 Gy group with regard to OS. Conclusions The analysis revealed that the 50.4 Gy group had a non-inferior outcome in comparison with the 60 Gy group for stages I, II/III and IV thoracic esophageal cancer. These results were obtained from a large database for the first time in Japan.


2020 ◽  
pp. 131-147 ◽  
Author(s):  
Eisuke Booka ◽  
Hiroya Takeuchi ◽  
Yuko Kitagawa

Sign in / Sign up

Export Citation Format

Share Document